Microbiology Nuts & Bolts
  • Home
  • Basic Concepts
    • What is infection?
    • Normal flora
    • Diagnosing infection
  • Microbiology
    • Basic bacterial identification
    • Interpreting bacteriology results
    • Interpreting serology results
  • Infection Control
    • What is infection control?
    • Universal precautions
    • MRSA
    • Clostridium difficile
  • Clinical Scenarios
    • Respiratory infections
    • Urinary infections
    • GI infections >
      • D&V
      • CDAD
    • CNS infections
    • Skin & bone infections
    • Sepsis
  • Antibiotics
    • Antimicrobial Stewardship
    • How antibiotics work
    • How to choose an antibiotic?
    • Reviewing antibiotics
    • Antibiotic resistance
    • Testing antibiotic resistance
    • Penicillin allergy
    • Theraputic Drug Monitoring
  • Guidelines
  • Lectures & Lecture Notes
    • Medical Students
    • Curriculum for the Foundation Program
    • Foundation Year 1
    • Foundation Year 2
    • Other Lectures
  • The Bug Blog
  • Buy the book...
  • NEW Edition Updates
  • Peer Reviews
  • Want to know more?
  • Contact

Coming out of lockdown, ready, steady… gone already!?

4/6/2020

 
So we have been let loose and lockdown is being de-escalated slowly but have we gone too soon? We don’t have a vaccine, treatments give only modest benefits and we’re not so good at social distancing on a beach! “Experts” are a little alarmed at the pace of release and I think we’re going to be stuck with Covid-19 for a while yet, so what shall I blog about this week?

One of the stories that keeps grumbling along in the background of Covid-19 is the potential to use antibodies from patients who have survived the infection to treat patients with active infection. It’s known as plasma therapy and it’s not as crazy it might at first sound.
Plasma Therapy
This is NOT Plasma Therapy!
​In fact using antibodies to treat infections is nothing new. Back in about 1900 Emil von Behring and Paul Ehrlich discovered a treatment for diphtheria by infecting a horse with the bacterium (Corynebacterium diphtheriae), taking that serum from the horse and then giving it to their patients with diphtheria (Note: do not do this! Ethical approval has changed radically since this time!). Although at the time Behring and Ehrlich were pleased with the results, they didn’t actually know why their new treatment worked; the serum contained antibodies which killed the bacterium and neutralised the toxin. It was brilliant!
 
Prior to this time diphtheria was a common cause of death and killed most of the children it infected; it must have been terrifying. This “new treatment” was revolutionary and quite rightly resulted in the award of the first Nobel prize for medicine (although it was only given to von Behring!). Today, we actually use antibody therapy in the management of infections on a regular basis, including still using antibodies to neutralise diphtheria toxin.
 
There are three types of preparations available to us…
 
Note: in medicine we use the term immunoglobulin (Ig) when we are talking about antibody… why? Just to be confusing I think….
 
Types of antibody preparation
There are 3 different types of antibody preparation used in the management of infection:
  • Intravenous immunoglobulin (IVIg) – this is immunoglobulin collected from multiple blood donors which is concentrated for use in other people. This type of Ig contains low concentrations of antibodies from multitudes of bacteria, viruses, etc. to which the donors had previously been exposed. It is not specific to any particular microorganism.
  • Pooled immunoglobulin – this is also immunoglobulin from multiple blood donors but it has been screened and concentrated to give high levels of Ig to a specific microorganism e.g. Varicella Zoster Ig, Hepatitis B Ig or Ebola Ig
  • Monoclonal antibodies – this Ig is made in a laboratory in genetically modified cells (usually myeloma cancer cells or even sometimes bacteria) that have been specifically chosen to target a particular molecule or microorganism e.g. RSV or Ebola. In fact Paul Ehrlich postulated this type of treatment and did finally get a Nobel Prize in 1908!
 
There are two ways we use antibody therapy: prevention and treatment…
 
Prevention of infection using antibodies
During the later stages of the immune response to infection the human body starts to produce antibodies. These antibodies eventually clear the infection, or at least suppress it so it no longer causes disease. Some of these antibodies become part of our long term immunity to future exposures to the disease.
 
So artificially giving protective antibodies to someone who has been exposed to an infectious microorganism can prevent the infection from occurring… just as if they had natural immunity from having had a previous infection or vaccination. This is sometimes called “passive immunity” as compared to “active immunity” which occurs as a result of vaccination or infection.
 
Passive immunity works if you have the antibodies before you are exposed or if the antibodies can be given within the incubation period of the disease to prevent infection from occurring (this can sometimes be a bit of a race, and the Microbiologist will have probably said something unhelpful like… “You’ll need to get this urgently from Pharmacy”… knowing full well its Sunday evening!).
 
All of our different types of antibody preparations can be used in these circumstances:
  • IVIg – this can be used to prevent measles in those who have been exposed to measles but who have not been vaccinated or might not respond to vaccine e.g. very young infants, pregnancy and immunocompromised patients. This relies on the fact that many blood donors have been immunised and therefore there are lots of relevant antibodies in the IVIg.
  • Pooled Ig – this can be used to prevent infection in non-immune patients who have been exposed to a certain microorganism e.g. exposure to chicken pox in pregnancy, the neonatal period or who are immunocompromised, or similarly given for exposure to hepatitis B in unvaccinated people, those who have received a high-risk exposure or those that have previously not responded to the vaccine.
  • Monoclonal antibody – this can be used to prevent infection in infants who are particularly at risk of severe bronchiolitis with Respiratory Syncytial Virus (RSV), the product is called Palivizumab.
 
Treating infection using antibodies
Antibodies can be used in the treatment of infections in order to help the patient’s immune system remove the infecting microorganism or neutralise toxins in order to prevent damage being done. In this situation the disease has already occurred, but the antibody is being used to stop it getting worse. This is what is being proposed for Covid-19 patients using pooled Ig; however this is still at an experimental stage.
 
All of our different types of antibody preparation can be used to treat infections:
  • IVIg – this type of preparation is often used to try and clear the patient’s blood stream of circulating toxins; it relies on either previous vaccination in blood donors e.g. tetanus, or donors having been previously exposed to a particularly common toxin mediated diseases which they have naturally controlled with their own immune response e.g. Panton Valentine Leukocidin Staphylococcus aureus, invasive Group A Beta-haemolytic Streptococcus, Clostridium perfringens gas gangrene and severe Clostridium difficile associated disease
  • Pooled Ig – this method has been used to treat severe infections using plasma taken from patients who have recovered from certain infections e.g. Ebola, SARS (classical)
  • Monoclonal antibody – during the West Africa outbreak of Ebola in 2014 a monoclonal antibody preparation called ZMapp was created by the Canadians and Americans to treat patients with Ebola. It is now produced by a company called LeafBio but it is still experimental.
 
So what about Covid-19?
So we are still in the experimental phase of the treatment of Covid-19. However Scientists are looking at all sorts of ways of trying to treat the infection. One of these ways is to develop antibody treatments in the same way as was used for SARS and Ebola. The 2 options are to use plasma from patients who have recovered from Covid-19; the other is to produce a monoclonal antibody.
 
Producing monoclonal antibodies is very difficult so plasma therapy is the main treatment being looked at. Essentially this would involve collecting blood from patients who have recovered from Covid-19, separating off the plasma, and then giving it by infusion to patients with active infection.
 
This sounds relatively straight forward as we have systems in place for donating blood and separating plasma already (great!!) BUT it isn’t actually that easy (Boo!!). In order for this to work you have to identify patients who have had Covid-19 and who ALSO have high levels of protective antibody.
 
It appears that ONLY those that have had severe infections actually produce a lot of antibody, so you’re donor has to have been a patient who was really unwell with Covid-19 AND survived. You also have to have a good test to detect antibodies in the plasma of the donors (which are only just becoming available now) AND only then can it be used to see if this new antibody treatment is effective at controlling the infection… and this is also currently a big unknown. Just how good are these antibodies?! And do they make people better or could they make people worse?
 
So we’re back to the clinical trials, again! Some patients with severe Covid-19 are now being given plasma therapy and we’ll have to wait and see whether this works. I think it might. The science is good, and it has been successfully done before with other diseases so hopefully it will work again. We’ll see.
 
P.S. Thank you Emil von Behring and Paul Ehrlich for your “dodgy ethical trials” in the 1900s, without you medicine might be at a loss.

Comments are closed.

    RSS Feed

    Facebook has deleted the Microbiology Nuts & Bolts pages - if you want your weekly dose of microbiology then you will need to come here, and we look forward to you continuing to read it!

    Blog Author:

    David Garner
    Consultant Microbiologist
    Surrey, UK

    Please DO NOT advertise products and conferences on our website or blog

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    Archives

    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    October 2013
    September 2013
    August 2013
    July 2013

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    RSS Feed

Powered by Create your own unique website with customizable templates.